The way that Pestel "tanked the FDA meeting" was by saying that we needed to try 350 mg before going to 700. He was concerned about safety and thought because it had never been tried in patients before with cancer and a cancer regimen that we should start with 350. I don't recall hearing that it was inside the FDA meeting. I thought it was in the hall during a shareholder meeting. At least that's what was communicated to me. A shareholder oversaw NP and P getting in a heated debate/argument about it.

While I think 350 is unnecessary, it is in the protocol even today.